CH667591A5 - Arzneimittel, die hydroxyprolin enthalten. - Google Patents
Arzneimittel, die hydroxyprolin enthalten. Download PDFInfo
- Publication number
- CH667591A5 CH667591A5 CH4616/85A CH461685A CH667591A5 CH 667591 A5 CH667591 A5 CH 667591A5 CH 4616/85 A CH4616/85 A CH 4616/85A CH 461685 A CH461685 A CH 461685A CH 667591 A5 CH667591 A5 CH 667591A5
- Authority
- CH
- Switzerland
- Prior art keywords
- hydroxyproline
- isomers
- amino acids
- cis
- mentioned
- Prior art date
Links
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 title claims 17
- 239000003814 drug Substances 0.000 title claims 15
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 title claims 14
- 229960002591 hydroxyproline Drugs 0.000 title claims 13
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 title claims 13
- 229940079593 drug Drugs 0.000 title claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 235000001014 amino acid Nutrition 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000004471 Glycine Substances 0.000 claims 3
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims 3
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims 3
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 claims 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 229960003067 cystine Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- -1 amino, hydroxyl Chemical group 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 201000007983 brain glioma Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical group O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000004292 cytoskeleton Anatomy 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000003978 infusion fluid Substances 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 231100000915 pathological change Toxicity 0.000 claims 1
- 230000036285 pathological change Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000005728 strengthening Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66820084A | 1984-11-05 | 1984-11-05 | |
| US72356585A | 1985-04-15 | 1985-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH667591A5 true CH667591A5 (de) | 1988-10-31 |
Family
ID=27099851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH4616/85A CH667591A5 (de) | 1984-11-05 | 1985-10-29 | Arzneimittel, die hydroxyprolin enthalten. |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPH0723309B2 (fr) |
| CA (1) | CA1281288C (fr) |
| CH (1) | CH667591A5 (fr) |
| DE (1) | DE3538619C2 (fr) |
| GB (1) | GB2171302B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0294380A4 (fr) * | 1986-02-18 | 1990-02-20 | Biota Scient Management | Stimulation de l'angiogenese. |
| DE3728852C2 (de) * | 1987-08-28 | 2003-06-18 | Wilhelm Hoerrmann | Arzneimittel zur Tumortherapie |
| EP0307390A3 (fr) * | 1987-09-04 | 1991-04-10 | Merckle Gmbh | Composé chimique consistant en cis-3-hydroxyproline pour un traitement thérapeutique et procédé de préparation |
| US5827874A (en) * | 1995-05-05 | 1998-10-27 | Meyer; Hans | Methods of treating pain and inflammation with proline |
| ES2152664T3 (es) * | 1996-03-11 | 2001-02-01 | Hoerrmann Wilhelm | Combinacion de cis-4-hidroxi-l-prolina y n-metil-cis-4-hidroxi-l-prolina para aplicacion como agente terapeutico, especialmente para el tratamiento contra el cancer. |
| AU2698997A (en) * | 1996-04-16 | 1997-11-07 | Chephasaar Chem.-Pharm. Fabrik Gmbh | Agent for inhibiting leukocyte invasion of tissues |
| DE10359829A1 (de) * | 2003-12-12 | 2005-07-21 | Salama, Zoser B., Dr.Rer.Nat. | Verwendung von CHP als Inhibitor von Glutathion-S-Transferasen und Kollagen IV |
| DE10359828A1 (de) * | 2003-12-12 | 2005-07-28 | Zoser B. Dr.Rer.Nat. Salama | CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe |
| US20080176923A1 (en) * | 2003-12-18 | 2008-07-24 | Salama Zoser B | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors |
| WO2005120495A1 (fr) * | 2004-06-14 | 2005-12-22 | Salama Zoser B | Composition anticancereuse composee de proline ou de ses derives et d'un anticorps antitumoral |
| EP1957066A4 (fr) | 2005-11-11 | 2013-08-28 | V Ravi Chandran | Acides amines acetyles en tant qu'agents antiplaquettaires, complements nutritifs et vitaminiques |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR7639M (fr) * | 1967-09-14 | 1970-02-02 | ||
| US3932638A (en) * | 1967-09-14 | 1976-01-13 | Franco-Chimie S.A.R.L. | Compositions and methods for wound healing |
| GB1399887A (en) * | 1971-06-10 | 1975-07-02 | Prockop D J | Composition and methods for controlling collagen synthesis |
| FR2207702B1 (fr) * | 1972-11-23 | 1975-11-28 | Rhone Poulenc Ind | |
| JPS59164718A (ja) * | 1983-03-10 | 1984-09-17 | Advance Res & Dev Co Ltd | 発癌予防剤 |
-
1985
- 1985-10-24 CA CA000493821A patent/CA1281288C/fr not_active Expired - Lifetime
- 1985-10-29 CH CH4616/85A patent/CH667591A5/de not_active IP Right Cessation
- 1985-10-30 DE DE3538619A patent/DE3538619C2/de not_active Expired - Lifetime
- 1985-11-04 GB GB8527159A patent/GB2171302B/en not_active Expired
- 1985-11-05 JP JP24642585A patent/JPH0723309B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE3538619C2 (de) | 1995-11-09 |
| JPS61155324A (ja) | 1986-07-15 |
| GB2171302A (en) | 1986-08-28 |
| DE3538619A1 (de) | 1986-05-07 |
| CA1281288C (fr) | 1991-03-12 |
| GB8527159D0 (en) | 1985-12-11 |
| GB2171302B (en) | 1989-08-23 |
| JPH0723309B2 (ja) | 1995-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69110101T2 (de) | GIP-Analoge und deren Verwendung. | |
| EP0357978B1 (fr) | Préparation pharmaceutique pour le traitement du diabète sucré | |
| DE3852086T2 (de) | Therapeutische Peptide. | |
| DE69713485T2 (de) | Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie | |
| DE69022678T2 (de) | S(+)-Ibuprofen-L-Aminosäure und S(+)-Ibuprofen-D-Aminosäure als Analgetika mit grösserem pharmakologischem Potential. | |
| DE2911670A1 (de) | Arzneimittel zur therapeutischen behandlung von peripheren vaskularen erkrankungen | |
| EP0185210B1 (fr) | Utilisation de dérivés dipeptidiques pour la préparation de médicaments pour le traitement des malades atteints de sclérose latérale amyotrophique | |
| DE3502041A1 (de) | Verwendung von dipeptidderivaten zur behandlung posttraumatischer nervenschaeden | |
| CH667591A5 (de) | Arzneimittel, die hydroxyprolin enthalten. | |
| DE3333640A1 (de) | Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung | |
| DE2705514C3 (de) | Nonapeptide und diese enthaltende Arzneimittel | |
| DE2052596A1 (de) | Neuartige Verwendung von N(6)-substituierten Adenosin-Derivaten | |
| Bernhard et al. | On the effects of xylocain on the central nervous system with special reference to its influence on epileptic phenomena | |
| DE69513324T2 (de) | L-Lysyl-Glycyl-L-Histidin und entsprechende pharmazeutische Zusammensetzungen zur Wundheilung | |
| CH649562A5 (de) | Derivate des methionin-enzephalins. | |
| Schwyzer et al. | Neue Synthesen auf dem Gebiete der melanophorenstimulierenden und corticotropen Hormone | |
| DE69120397T2 (de) | Physiologisch aktive substanzen, die gut zum durchdringen biologischer membranen befähigt sind | |
| DE3518078A1 (de) | Arzneimittel, die derivate des prolin oder hydroxyprolin enthalten | |
| DE2126533A1 (de) | Verfahren zur Herstellung pharma zeutischer Zubereitungen | |
| DE3239710C2 (de) | Peptid mit Nerven-regenerierenden Eigenschaften | |
| DE1518057B2 (de) | Injizierbares adrenocorticotropes hormonpraeparat mit prolongierter acthaktivitaet | |
| DE3416374C2 (fr) | ||
| DE2117762A1 (de) | Behandlung von Alopecia und pharmazeutische Präparation für die Durchführung der Behandlung | |
| DE3744542B4 (de) | Pharmazeutische Verwendung von L-δ-Hydroxylysin | |
| EP0036514B1 (fr) | Utilisation d'une substance obtenue du sérum sanguin pour stabiliser des prostaglandines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |